FIRST SHIPMENT OF IMMULINA DELIVERED TO SCN’S NEW IMMULINA PARTNER AERUS
In accordance to plan SCN has now received and delivered the first order from Aerus, SCN’s new Immulina partner, on totally USD 480 000 with cash payment. Aerus has also committed to purchase Immulina at a value of MSEK 250 during the coming six years in order to maintain the world-wide distribution rights. SCN also expects another order of the same size during this year.
As a consequence of this agreement and other actions that have been taken and implemented during the last six months, the SCN management believes that positive cash flow will be shown during the third and fourth quarter.
For more information, please contact:
Ulf Söderberg, CEO, email@example.com, +46 708 13 22 81
Jörn Erik Aas, Chairman of the Board, firstname.lastname@example.org, +47 924 99 360
Scandinavian Clinical Nutrition i Sverige AB (publ)) works in R&D and distribution of clinically tested, scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as thin400, CUUR, Coldizin, Immulina, Membra7 and Ledactin. Core competence and strategic alliances, within both R&D and sales, in combination with innovative and clinically proven products, create good conditions for profitable growth both in Sweden and internationally. The shares of SCN are traded under the ticker “SCN” on Oslo Axess (www.osloaxess.no) and NGM Equity (www.ngm.se).For more information, please visit www.scnutrition.com.